Lower-dose abiraterone demonstrated comparable efficacy to standard-dose abiraterone, positioning itself as a viable alternative for patients with mCRPC, according to data presented at #ASCO25. | @minitjshah urologytimes.com/view/lower-dos…
Big congrats to Dr. Sudeep Gupta & TMH Breast DMG team! New JCO Global Oncology study of 1,004 HER2+ BC patients on NAT. ✅ pCR: 22.5% → OS 87.3% vs 64.7% (no pCR) 💉 Trastuzumab >24w = best OS (80.5%) ⚠️ Baseline tumor burden prognostic even after pCR Access + duration…
Indian real-world data (@JCOGO_ASCO) confirms trastuzumab before/after surgery + maintenance enhances survival in HER2-positive breast cancer, esp when pCR achieved. Need early dx & universal access to HER2 drugs in LMICs. doi.org/10.1200/GO-24-… #GlobalOnc
Gef vs Gef plus Pemetrexed & Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial A paper very close to our hearts, true reflection of the hard work of our solid unit 2 department. jamanetwork.com/journals/jamao… jamanetwork.com/journals/jamao…
Neoadjuvant chemotherapy in locally advanced Sinonasal Teratocarcinosa... sciencedirect.com/science/articl… @DrVijayPatil11 @VanitaNoronha @minitjshah
A much awaited answer from our Solid Tumour Unit 2 group at Tata Memorial Center. Congratulations Dr Vanita, Dr Vijay, Dr Kumar sir and the entire Solid Tumour Unit 2 team!!!! ejcancer.com/article/S0959-…
Parween et al. present a pan-cancer analysis of homologous recombination DNA repair pathway genes in the Indian population. Read here: bit.ly/3GXbtvh #CancerResearch #CRST #Oncology #DNA #MedTwitter
So proud of the junior most member of our team at @TataMemorial- Dr Minit Shah. Thanks @EvelynWongYT for highlighting this. @Nandinimenon18 @DrVijayPatil11 @ajaysinghmedonc @tmhmedoncalumni @KNJobanputra
Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
Long term outcomes of phase I/II study of palliative triple metronomic... sciencedirect.com/science/articl… @DrVijayPatil11
Metrnomic adjuvant after definitive CTRT in HNSCC is it usefull? Read our phase 3 study for the answer. @VanitaNoronha @AnticancerOrgUK @Nandinimenon18 @H_N_C_I_G @DrEzraCohen @DrHaddadRobert @docdcruz @drprathameshpai @venkymd @ashayoncology sciencedirect.com/science/articl…
United States 趨勢
- 1. Ohtani 204K posts
- 2. Dodgers 249K posts
- 3. Dodgers 249K posts
- 4. Carson Beck 16.2K posts
- 5. $SAWA 1,672 posts
- 6. Miami 99.2K posts
- 7. Louisville 27.8K posts
- 8. Nebraska 17.7K posts
- 9. Brewers 55.1K posts
- 10. Babe Ruth 3,204 posts
- 11. Emiru 5,375 posts
- 12. NLCS 58.3K posts
- 13. #SmackDown 56.6K posts
- 14. #BostonBlue 7,772 posts
- 15. Rhule 4,581 posts
- 16. Minnesota 47.5K posts
- 17. 3 HRs 10K posts
- 18. George Santos 80.7K posts
- 19. 10 Ks 4,434 posts
- 20. Massie 28.6K posts
Something went wrong.
Something went wrong.